Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Sep 20;9(4):100583. doi: 10.1016/j.hjdsi.2021.100583

Association of Social Vulnerability, COVID-19 vaccine site density, and vaccination rates in the United States

Nitya Thakore a, Rohan Khazanchi b,c, E John Orav a,d, Ishani Ganguli a,e,
PMCID: PMC8450273  PMID: 34560408

Abstract

The COVID-19 pandemic has disproportionately impacted Americans in socially vulnerable areas. Unfortunately, these groups are also experiencing lower vaccination rates. To understand how strategic vaccine site placement may benefit high vulnerability populations, we extracted vaccine site locations for 26 U.S. states and linked these data to county-level adult vaccination rates and the CDC 2018 Social Vulnerability Index rankings. We fit quasi-Poisson regression models to compare vaccine site density between the highest and lowest SVI domain quartiles, and assessed whether greater vaccine site density mediated or modified the relationship between social vulnerability and vaccination rates. We found that high vulnerability counties by socioeconomic status had more vaccine sites per 10,000 residents, yet this higher vaccine site density did not reduce socioeconomic disparities in vaccination rates. Persistent vaccination inequities may reflect other structural barriers to access. Our results suggest that targeted vaccine site placement in high vulnerability counties may be necessary but insufficient for the goal of widespread, equitable vaccination.

Keywords: COVID-19, Vaccination, Healthcare access

1. Introduction

The COVID-19 pandemic has disproportionately impacted socially vulnerable populations across the U.S.1 Unfortunately, these groups have also had lower vaccination rates.2 , 3 If vaccine sites are strategically placed in high vulnerability counties, as several state implementation plans attempted,4, 5, 6 this may facilitate equitable distribution.7 Yet, the potential benefits of county-level targeted site placement may be offset by non-residents receiving vaccines at these sites or by other structural barriers limiting access for populations at greatest risk.8 , 9

Across metropolitan and non-metropolitan U.S. counties, we examined relationships between social vulnerability, vaccine site density (sites per 10,000 residents), and vaccination rates as of April 2021. We sought to understand how vaccine site placement may benefit high vulnerability populations by assessing whether greater vaccine site density mediated or modified the relationship between social vulnerability and vaccination rates.

2. Materials and methods

We determined county-level vaccine site density by extracting COVID-19 vaccine site addresses from health department websites of the 26 states with reliable data (i.e., regularly updated and inclusive of vaccine site types ranging from state mass vaccination sites and local health department clinics to private medical offices and pharmacies) as of 4/1/2021. We validated county assignments as needed using a geocoding application (Geocodio) (details in Appendix).

We linked vaccine site density data to county-level adult vaccination rates from the U.S. Centers for Disease Control and Prevention (CDC) as of 4/1/202110; the CDC 2018 Social Vulnerability Index (SVI) domains (socioeconomic status [SES], household composition/disability, minority status/language, and housing/transportation)11; and urbanicity, defined by the U.S. Department of Agriculture's 2013 Urban Influence Codes.12

We fit quasi-Poisson regression models to compare vaccine site density between the highest and lowest SVI domain quartiles. We fit linear regression models to assess associations between SVI domains and county vaccination rates, controlling for percent population ≥65-years-old. For the SVI domain most strongly associated with vaccination rates (based on partial R2), we added county-level vaccine site density to the model as a potential mediator. We then assessed if site density modified the relationship between social vulnerability and vaccination rates by adding interaction terms between the continuous SVI domain index score and indicators for counties in the highest and lowest quartiles of vaccine site density. Comparing the slopes of the SVI domain index score between counties with the highest and lowest vaccine site densities allowed us to see whether disparities in vaccination rates were worse in counties with few vaccination sites. In secondary analyses, we stratified counties by urbanicity. All models were population-weighted and included state fixed effects to account for heterogeneity in vaccine policy.

We used R Statistical Software, v4.0.5 and considered 2-sided P < 0.05 significant. The Mass General Brigham Review Board waived study review.

3. Results

We identified 22,480 vaccine sites across 1738 counties (mean 2.17 per 10,000 residents, SD 2.22; median 1.50, IQR 0.85–2.73). States with the highest mean county-level site densities were North Dakota (8.15) and Alaska (4.62); those with the lowest were Massachusetts (0.53) and Rhode Island (0.66).

Overall SVI was not associated with vaccine site density (Table 1 ). However, the most vulnerable counties by SES and household composition/disability SVI domains had higher vaccine site density than the least vulnerable (adjusted risk ratio [aRR] 1.25; 95%CI 1.16–1.34 and 1.33; 95%CI 1.25–1.42, respectively). The most vulnerable counties by minority status/language had lower vaccine site density (aRR 0.73; 95%CI 0.67–0.79).

Table 1.

Vaccine site density by social vulnerability across metropolitan and non-metropolitan counties.

COVID-19 Vaccine Sites per 10,000 Residentsa
N = 1738 counties
Q1 Q2 Q3 Q4 Adjusted Risk Ratio for Q4/Q1b (95% CI)
Social Vulnerability Indexc 1.22 (1.08) 1.34 (1.07) 1.12 (0.960) 1.29 (0.963) 1.06 (0.985, 1.13)
Metropolitand 1.11 (0.853) 1.24 (0.957) 1.00 (0.786) 1.10 (0.760) 0.936 (0.865, 1.01)
Non-metropolitand 2.03 (1.93) 1.96 (1.48) 2.23 (1.53) 1.93 (1.25) 1.08 (0.961, 1.22)
Socioeconomic Statuse 1.21 (1.05) 1.10 (0.940) 1.23 (0.981) 1.67 (1.12) 1.25*** (1.16, 1.34)
Metropolitan 1.12 (0.869) 1.02 (0.810) 1.08 (0.797) 1.48 (0.959) 1.04 (0.940, 1.14)
Non-metropolitan 2.17 (2.03) 1.95 (1.55) 2.20 (1.42) 1.88 (1.24) 1.06 (0.936, 1.21)
Household Composition/Disabilityf
1.05 (0.958) 1.16 (0.882) 1.39 (1.01) 1.86 (1.27) 1.33*** (1.25, 1.42)
Metropolitan 0.989 (0.836) 1.07 (0.736) 1.23 (0.827) 1.65 (1.06) 1.13** (1.03, 1.23)
Non-metropolitan 2.12 (1.93) 1.91 (1.45) 1.99 (1.37) 2.09 (1.43) 1.16** (1.05, 1.28)
Minority Status/Languageg 1.94 (1.54) 1.65 (1.18) 1.44 (1.11) 1.01 (0.797) 0.725*** (0.666, 0.789)
Metropolitan 1.43 (0.866) 1.46 (0.948) 1.36 (1.03) 0.954 (0.708) 0.948 (0.825, 1.09)
Non-metropolitan 2.28 (1.78) 1.97 (1.44) 1.87 (1.40) 2.04 (1.39) 0.932 (0.825, 1.05)
Housing/Transportationh 1.19 (1.08) 1.38 (1.07) 1.26 (0.961) 1.12 (1.00) 1.01 (0.942, 1.08)
Metropolitan 1.08 (0.835) 1.23 (0.834) 1.16 (0.859) 0.973 (0.809) 0.968 (0.894, 1.05)
Non-metropolitan 1.94 (1.93) 1.97 (1.56) 2.13 (1.27) 2.04 (1.46) 0.918 (0.828, 1.02)

Data extracted on April 1, 2021.

***p < 0.001, **p < 0.01, *p < 0.05.

Q1 = least vulnerable quartile to Q4 = most vulnerable quartile. Q1, Q2, Q3 and Q4 are reported as mean (SD) values, weighted by county population.

a

Vaccine site density was constructed using counts of vaccine sites (including private sites such as pharmacies and medical offices, state mass vaccination sites, and local health departments) in a given county as well as population size for the county.

b

Q4/Q1 adjusted risk ratios and 95% confidence intervals were calculated from population-weighted quasi-Poisson regression models with state fixed effects.

c

The Social Vulnerability Index is an aggregate of all four domains, each calculated based on variables from the 2014–2018 US Census American Community Survey data.

d

Metropolitan and non-metropolitan designations were determined from the 2013 Urban Influence Codes: 1–2 were classified as “Metropolitan”, while 3–12 were classified as “Non-Metropolitan.”

e

The Socioeconomic Status domain includes income, poverty, employment, and education variables.

f

The Household Composition/Disability domain includes dependent children less than 18 years of age, persons 65 and older, single-parent households, and people with disabilities.

g

The Minority Status/Language domain includes race, ethnicity, and English language proficiency variables.

h

The Housing Type/Transportation domain includes housing structure, crowding, and vehicle access variables.

Among included counties, mean adult vaccination rate was 19.6% (SD 8.5). The SES domain had the strongest association with vaccination rates (partial R2 = 0.069); counties in higher SES vulnerability quartiles (Q2-Q4) had 1.8, 2.2, and 3.9 percentage-point lower vaccination rates, respectively, than counties in the least vulnerable quartile (Table 2 ). When including vaccine site density in the model, each additional vaccine site per 10,000 residents was associated with a 0.65 percentage-point increase in vaccination rates. However, site density did not mediate the association between SES vulnerability and vaccination rate overall or within metropolitan and non-metropolitan counties.

Table 2.

Association of adult COVID-19 vaccination rate with socioeconomic vulnerability and vaccine site density.

Adult COVID-19 Vaccination Ratea
All Counties
N = 1483
Metropolitan Countiesb
N = 595
Non-metropolitan Countiesb
N = 888
A B A B A B
Socioeconomic Statusc, Q2 −1.81*** (0.274) −1.86*** (0.273) −1.72*** (0.390) −1.73*** (0.389) −2.53*** (0.580) −2.59*** (0.576)
Socioeconomic Status, Q3 −2.24*** (0.290) −2.32*** (0.289) −2.23*** (0.414) −2.25*** (0.413) −2.29*** (0.622) −2.37*** (0.618)
Socioeconomic Status, Q4 −3.93*** (0.419) −4.16*** (0.423) −4.59*** (0.732) −4.70*** (0.732) −2.61*** (0.689) −2.71*** (0.685)
Vaccine Sites per 10,000 Residents 0.654*** (0.194) 0.997* (0.481) 0.609*** (0.166)

Data extracted on April 1, 2021.

***p < 0.001, **p < 0.01, *p < 0.05.

Q1 = least vulnerable quartile; Q4 = most vulnerable quartile. Standard errors in parenthesis.

Regression coefficients in columns labeled as (A) included SES vulnerability quartiles as predictors and vaccination rate as the outcome. Regression coefficients in columns labeled as (B) additionally included vaccine site density as a potential mediator. All regressions are weighted by county population, adjusted for state fixed effects, and adjusted for the proportion of the population ≥65 years old.

a

County-level vaccination rate was defined as percent of the population ≥18 years old with a completed vaccination series. Counties in Texas and one county in Alaska did not have vaccination rate data and were not included.

b

Metropolitan and non-metropolitan designations were determined from the 2013 Urban Influence Codes: 1–2 were classified as “Metropolitan”, while 3–12 were classified as “Non-Metropolitan.”

c

The Socioeconomic Status domain of the Social Vulnerability Index includes income, poverty, employment, and education variables.

Across levels of SES vulnerability, counties with high vaccine site density had higher vaccination rates than counties with low site density (Fig. 1 ). However, vaccine site density did not modify the relationship between SES and vaccination rates: there was no significant difference in the slope of the SVI SES domain index score between counties with low and high site density. These patterns persisted within metropolitan counties and within non-metropolitan counties.

Fig. 1.

Fig. 1

Association of Adult COVID-19 Vaccination Rate with Socioeconomic Vulnerability in Counties with High and Low Vaccine Site Densitya.

a The county-level vaccination rate by socioeconomic vulnerability rank in the lowest (N = 408) and highest (N = 359) vaccine site density quartile. County-level vaccination rate was defined as percent of the population ≥18 years old with a completed vaccination series. Counties in Texas and one county in Alaska did not have vaccination rate data and were not included. The linear model to compare slopes between low and high site density counties included vaccination rate as the outcome, and SES vulnerability, a binary variable for high vaccine site density counties, and their interacted term as predictors. The regression was weighted by county population and adjusted for state fixed effects and the proportion of the population ≥65 years old.

4. Discussion and conclusions

In this cross-sectional study of COVID-19 vaccination rates and vaccine site density across the United States, counties with high SES vulnerability had greater vaccine site density than those with low vulnerability. As expected, greater vaccine site density was associated with higher vaccination rates for counties at all levels of SES. However, greater vaccine site density did not reduce socioeconomic inequities in vaccination rates.

The most vulnerable counties by socioeconomic status had more vaccine sites per capita, which may reflect targeted placement efforts or increased prevalence of community vaccination venues in low-income areas. Counties with high vulnerability by minority status/language had fewer sites, perhaps due to downstream consequences of structural racism on the geographic maldistribution of underlying infrastructure to establish sites. For these counties, unavailability of vaccine sites may have compounded other structural barriers to vaccine uptake.

Consistent with other studies, we found a strong association between socioeconomic vulnerability and low vaccination rates that has persisted since our data collection.2 , 3 , 13 While counties with higher SES vulnerability had more vaccine sites per capita, this increased site density did not mitigate the association of SES with lower vaccination rates. Persistent vaccination inequities may have reflected non-residents using the sites and limited vaccine supply, as well as other access challenges related to lack of transportation and inflexible time-off policies for working class employees.14 , 15 Technological barriers in obtaining vaccine appointments, such as lack of internet access or technology literacy, may also have played a role.9 Since April 2021, vaccine supply barriers have largely disappeared in the U.S,16 but the other barriers persist alongside widening ideological divisions in public opinion about vaccination. 17 , 18

This cross-sectional study has limitations: our results reflect one point in time during a rapidly evolving pandemic. Vaccine site data on health department websites may be incomplete, and we could not account for heterogeneity in vaccine site capacity. 19 , 20 While our sample of 26 states is large, our findings may not reflect the remaining 24 states. Finally, our analysis does not capture within-county heterogeneity in vaccine site density and SES, though our level of analysis aligns with the growing use of county-level SVI in vaccine targeting.5 , 6

Our results suggest that targeted vaccine site placement in high vulnerability counties may be necessary but insufficient for the goal of widespread, equitable vaccination. Vaccines should be strategically allocated in tandem with policy interventions to address structural access barriers.9 , 14 , 15

Financial Support

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Role of Funder

N/A.

Reproducible Research Statement

Study protocol: Not applicable. Statistical code: Available upon request from Ms. Thakore (Nitya.Thakore@nyulangone.org). Data availability: Vaccine site location data are available upon request from Ms. Thakore (Nitya.Thakore@nyulangone.org). Other datasets analyzed for this study are readily available from the public repositories listed in the references.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Ganguli reports consulting fees from F-Prime and Blue Cross Blue Shield Massachusetts for work unrelated to this research. No other authors have relevant conflicts of interest to report.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.hjdsi.2021.100583.

Appendix A. Supplementary data

The following is/are the supplementary data to this article:

Multimedia component 1
mmc1.docx (14.4KB, docx)

References

  • 1.Khazanchi R., Beiter E.R., Gondi S., Beckman A.L., Bilinski A., Ganguli I. County-level association of social vulnerability with COVID-19 cases and deaths in the USA. J Gen Intern Med. 2020;35:2784–2787. doi: 10.1007/s11606-020-05882-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Hughes M.M., Wang A., Grossman M.K., et al. vol. 70. Centers for Disease Control and Prevention (CDC); 2021. (County-Level COVID-19 Vaccination Coverage and Social Vulnerability — United States, December 14, 2020–March 1, 2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Barry V. Patterns in COVID-19 vaccination coverage, by social vulnerability and urbanicity — United States, December 14, 2020–May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;2021:70. doi: 10.15585/MMWR.MM7022E1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Arling G., Blaser M., Cailas M., et al. A data driven approach for prioritizing COVID-19 vaccinations in the midwestern United States. Online J. Public Health Inform. 2021;13 doi: 10.5210/ojphi.v13i1.11621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Schmidt H., Weintraub R., Williams M.A., et al. Equitable Allocation of COVID-19 vaccines in the United States. Nat Med. 2021:1–10. doi: 10.1038/s41591-021-01379-6. [DOI] [PubMed] [Google Scholar]
  • 6.Ndugga N., Artiga S., Pham O. How are states addressing racial equity in COVID-19 vaccine efforts? https://www.kff.org/racial-equity-and-health-policy/issue-brief/how-are-states-addressing-racial-equity-in-covid-19-vaccine-efforts/ Available online: 4 June 2021.
  • 7.Bibbins-Domingo K., Petersen M., Havlir D. Taking vaccine to where the virus is—equity and effectiveness in coronavirus vaccinations. JAMA Heal. Forum. 2021;2 doi: 10.1001/jamahealthforum.2021.0213. [DOI] [PubMed] [Google Scholar]
  • 8.Goodnough A., Hoffman J. 2021. Even in Poorer Neighborhoods, the Wealthy Are Lining up for Vaccines - the New York Times. New York Times. [Google Scholar]
  • 9.Press V.G., Huisingh-Scheetz M., Arora V.M. Inequities in technology contribute to disparities in COVID-19 vaccine distribution. JAMA Heal. Forum. 2021;2 doi: 10.1001/jamahealthforum.2021.0264. [DOI] [PubMed] [Google Scholar]
  • 10.Covid Data Tracker Centers for Disease Control and Prevention. 2020. https://covid.cdc.gov/covid-data-tracker/#datatracker-home
  • 11.CDC's social vulnerability index 2018 database 2018. Centers for Disease Control and Prevention. https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html
  • 12.2013. USDA ERS - urban influence codes.https://www.ers.usda.gov/data-products/urban-influence-codes/dataset [Google Scholar]
  • 13.Brown C.C., Young S.G., Pro G.C. COVID-19 vaccination rates vary by community vulnerability: a county-level analysis. Vaccine. 2021;39:4245–4249. doi: 10.1016/J.VACCINE.2021.06.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Corbie-Smith G. Vaccine hesitancy is a scapegoat for structural racism. JAMA Heal. Forum. 2021;2 doi: 10.1001/jamahealthforum.2021.0434. [DOI] [PubMed] [Google Scholar]
  • 15.Fowers A. 2021. Concerns about Missing Work May Be a Barrier to Coronavirus Vaccination - the Washington Post. Washington Post. [Google Scholar]
  • 16.Wright W., McDonnell Nieto del Rio G. 2021. A New Covid Dilemma: What to Do when Vaccine Supply Exceeds Demand? - the New York Times. New York Times. [Google Scholar]
  • 17.Metzl J.M. Basic Books; 2019. Dying of Whiteness : How the Politics of Racial Resentment Is Killing America's Heartland. ISBN 9781541644960. [Google Scholar]
  • 18.Kates J., Tolbert J., Orgera K. The red/blue divide in COVID-19 vaccination rates is growing | KFF available online. https://www.kff.org/policy-watch/the-red-blue-divide-in-covid-19-vaccination-rates-is-growing/
  • 19.Howe J.L., Young C.R., Parau C.A., Trafton J.G., Ratwani R.M. Accessibility and usability of state health department COVID-19 vaccine websites: a qualitative study. JAMA Netw. Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.14861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hogan T.H., Sieck C.J., Menser T. A review of state health department COVID-19 websites: concerns and recommendations | health affairs. Health Aff. 2021 doi: 10.1377/hblog20210226.583970. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.docx (14.4KB, docx)

Articles from Healthcare (Amsterdam, Netherlands) are provided here courtesy of Elsevier

RESOURCES